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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) and gallstone disease (GD) are both highly prevalent in the general
population and associated with obesity and insulin resistance. We aimed to evaluate the prevalence of GD in a cross
sectional study of NAFLD patients and to define whether the presence of GD is associated with diabetes and predicts more
severe liver disease.
Methodology/Principal Findings: We merged databases of four Liver Units, comprising 524 consecutive biopsy-proven
NAFLD (373 males) observed between January 2003 and June 2010. GD was diagnosed in 108 (20%), and 313 cases (60%)
were classified by liver biopsy as nonalcoholic steatohepatitis (NASH). The GD subgroup was characterized by a significantly
higher prevalence of females, prediabetes/diabetes, abdominal obesity and metabolic syndrome, older age, higher BMI,
fasting glucose, HOMA-IR and lower ALT. The prevalence of GD progressively increased with advancing fibrosis and with the
severity of necroinflammatory activity (p for trend = 0.0001 and = 0.01, respectively), without differences in the severity of
steatosis. At multivariate analysis GD was associated with female gender (OR 1.37, 95% CI 1.04–1.8), age (OR 1.027, 95%
CI1.003–1.05), fasting glucose (OR 1.21, 95% CI 1.10–1.33) and NASH (OR 1.40,95% CI 1.06–1.89), whereas ALT levels were
associated with a lower GD risk (OR 0.98, 95% CI 0.97–0.99). When subjects with cirrhosis were excluded from analysis, the
association between GD and fasting glucose, female gender, and NASH was maintained.
Conclusion: Patients with NAFLD have a high prevalence of GD, which characterizes subjects with altered glucose
regulation and more advanced liver disease.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) includes a wide
spectrum of liver conditions ranging from pure fatty liver, usually
a benign and non-progressive condition, to non-alcoholic steatohe-
patitis (NASH), which may eventually progress to cirrhosis, portal
hypertension and hepatocellular carcinoma [1,2,3]. Hepatic insulin
resistance, associated with obesity, type 2 diabetes and dyslipidemia,
is the underlying metabolic milieu favoring the occurrence of
NAFLD [4], also accounting for the risk of progressive liver disease
observed in these patients. NAFLD is now considered the hepatic
expression of the metabolic syndrome [3,4,5,6]; as such it is also
associated with a high risk of cardiovascular disease [7,8,9].
Gallstone disease (GD) is one of the most common disorders of
the gastrointestinal tract. Overall, the prevalence of gallstones in
the general population is approximately 10–15% in the U.S. [10]
and 9.5–18.9 in Italy [11]. The very high prevalence of both GD
and NAFLD makes it very likely a chance co-occurrence in a high
number of cases, but NAFLD and GD also share common risk
factors. Both diseases are associated with overweight/obesity,
hypertriglyceridemia, insulin resistance, and type 2 diabetes
mellitus, and their coexistence might also be pathogenically
mediated [12,13,14].
Recent experimental studies report that hepatic insulin resistance
may be associated with biliary cholesterol secretion, thus promoting
cholesterol gallstone formation [15,16]. Hyperinsulinemia may
increase hepatic cholesterol secretion, biliary cholesterol super-
saturation and gallbladder dysmotility, all favoring gallstone
formation, whereas insulin resistance has been associated with GD
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even in non-diabetic, non-obese individuals [17], thus providing a
link between the metabolic syndrome and gallstone susceptibility.
Methods
Objectives
Aim of the present study was to evaluate the prevalence of GD
and associated factors in a large series of patients with
histologically proven NAFLD and to define whether the presence
of GD is associated with type 2 diabetes and predicts more severe
liver disease of metabolic origin.
Patients
We merged the databases of four Liver Units, all referral centers
for metabolic liver disease, long working together with shared
protocols [18,19]. The Case Report Form used by the centers was
the basis of a collaborative Italian study sponsored by the Italian
Association for the Study of the Liver on Liver Fat (Steatosi
Epatica - STEP study). Consecutive patients submitted to a
diagnostic liver biopsy between January 2003 and June 2010 were
included in the study, provided that the tissue sample size was
$1.7 cm. No cases had liver biopsy during cholecistectomy.
The final cohort comprised 524 NAFLD cases, in which all
other causes of liver diseases (viral, autoimmune, drug-induced,
hereditary hemochromatosis, Wilson’s disease) had been excluded
and whose daily alcohol intake, confirmed by at least one family
member, was #20 g. Liver biopsy had been performed in the
presence of long-lasting elevation of liver enzymes and/or ferritin,
coupled with a long history of steatosis [18]. Cases diagnosed as
fibrosis stage 4 at histology [20,21] were considered as having
cirrhosis, but were maintained in the analysis. By contrast, subjects
with clinical or sonographic evidence of decompensated cirrhosis
and a limited number (5 cases) of subjects of non-Caucasian origin
were excluded.
Ethics
The observational study protocol was first approved by the
Institutional Review Board (IRB) of ‘‘Ca’ Granda’’ IRCCS
Foundation, Ospedale Maggiore Policlinico, Milan, Italy, regulat-
ing the activity of the Liver unit that designed the study and
coordinated data collection, while for the other Liver Units, once
approval of the proponent center was obtained only a notification
of the study to the IRBs local Institutions was required. Written
consent was provided by patients for data storing in the hospital
database and use for research. The study conforms to the ethical
guidelines of the 1975 declaration of Helsinki.
Methods
At enrollment lifestyle habits, clinical and pharmacological
history, BMI, waist circumference (measured at the level of the
umbilicus, at the midlevel between the lowest rib and the iliac
crest, with the subject standing and breathing normally) and
arterial blood pressure (defined as the mean of the second and
third reading of three consecutive blood pressure measurements),
complete blood count, alanine and aspartate aminotransferase
(ALT-AST) gamma-glutamyltransferase (GGT), serum alkaline
phosphatase (SAP) and bilirubin, fasting glucose, total and HDL
cholesterol, triglycerides, and uric acid, were available in all
subjects, determined by determined standard laboratory proce-
dures and insulin had been measured by a commercially
purchased radioimmunoassay (RIA, Biochem Immunosystems,
Bologna, Italy), used in the participating Units. The metabolic
syndrome was diagnosed according to the presence of 3 or more of
the revised ATPIII criteria [22].
Insulin resistance was evaluated according to the homeostatic
model assessment (HOMA) [23]. An oral 75 g glucose tolerance
test (OGTT) had been performed in all subjects without diabetes
according to World Health Organization criteria. The presence of
diabetes (fasting glucose $7 mmol/l, 120-min glucose during
OGTT $11.1 mmol/l, or treatment with glucose-lowering drugs),
obesity (BMI .30 kg/m2) and overweight (BMI, 25–29.9 kg/m2)
were also recorded.
Liver Histology
Liver biopsies were processed routinely, and read by a single
pathologist in each centre. To control for biopsy size, the length of
the biopsy was measured with a hand ruler, and the number of
portal areas on a cross-section was counted. The minimum biopsy
size for inclusion in the study was 1.7 cm and the number of portal
areas was 10. Steatosis was graded 1 to 3 according to the
percentage of cells with fatty droplets (grade 1: 10–33%, 2: 33–
66% and 3.66%). NASH was diagnosed by experienced
pathologists according to standard criteria; their agreement was
checked in this as in other studies as part of common granted
protocols.
Definition of Gallstone Disease (GD)
Ultrasonography had been performed per protocol for the
evaluation of steatosis at time of biochemistry evaluation.
Gallstone disease was diagnosed in the presence of one of the
following criteria: (i) sonographic evidence of gallstones (one or
more echogenic, distally shadowing, possibly movable structures in
the gallbladder); (ii) echogenic material within the gallbladder with
constant shadowing and little or no visualization of the gallblad-
der; and (iii) absence of gallbladder at ultrasonography, coupled
with a history of cholecystectomy (in 14 cases).
Statistical Analysis
Results are expressed as means 6 standard deviations for
continuous variables and as frequencies for categorical variables.
Mean values were compared by t-test for unequal variances.
Frequencies were compared by chi-square test. P values #0.05
were considered statistically significant. Continuous variables were
correlated by Spearman test. Logistic regression analyses were
performed to assess the variables independently associated with the
presence of NASH and moderate-to-severe fibrosis (stage $2).
This cut-off was chosen because of the relatively mild fibrosis
detected in our patients. Variables significant at univariate
analyses were entered in a multivariate analysis. All statistical
analyses were performed by the JMP statistical discovery software
system (SAS, Cary, NC).
Results
GD was diagnosed in 107/524 (20%) NAFLD patients by
sonographic scanning and in 14 (13%) on the basis of previous
cholecystectomy.
At histology, 343 cases (65.5%) had minimum (stage 1) or no
fibrosis, 111 had fibrosis stage 2 (21.5%), 37 had fibrosis stage 3
(7.1%) and 33 (6.3%) were classified as cirrhosis (stage 4 fibrosis).
The prevalence of GD progressively increased with advancing
fibrosis from about 15% (stage 0–2) to 29% (stage 3) and 56%
(stage 4), and with the severity of necro-inflammatory activity from
14% (grade 0–1), to 23% (grade 2–3), 28% (grade 4) and 35%
(grade .4), (p for trend = 0.0001 and = 0.01, respectively),
without differences in the severity of steatosis (Figure 1).
Three hundred and sixteen cases were diagnosed with NASH,
and the prevalence of NASH was significantly higher in the
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presence of GD (82/107 (77%) vs. 231/417 (56%) without GD,
p= 0.0001).
One hundred forty-four patients had diabetes. In 106 cases, the
diagnosis preceded NAFLD (by 77670 months), in the remaining
38 the diagnosis was contemporary to that of NAFLD. Mean
HbA1c was 7.264.8% without difference between patients with or
without GD. In patients with a known history of diabetes HbA1c
was higher. Of the 106 patients with a previous diagnosis of
diabetes, 27 were treated with insulin, 47 with oral hypoglycaemic
agents and 32 with diet only. Twenty-eight cases with diabetes had
cirrhosis.
Compared with cases with no GD, the GD group was
characterized by a significantly higher prevalence of female
gender, prediabetes/diabetes, abdominal obesity, metabolic syn-
drome, older age, as well as higher BMI, fasting glucose, HOMA-
IR, higher AST/ALT ratio and lower ALT (table 1). After
exclusion of subjects with cirrhosis, the presence of GD remained
significantly associated with female gender (OR 1.45; 95% CI
1.13–1.85), age (OR 14, 95% CI 4.1–51.2), AST/ALT (OR 2.6,
95% CI 1.33–5.2), ALT (OR 0.99, 95% CI 0.98–0.99), fasting
glucose (OR 1.19, 95% CI 1.06–1.32), presence of MS (OR 1.29,
95% CI 1.07–1.65) and NASH (OR 1.47 95% CI 1.15–1.92). In
particular, the presence of prediabetes (impaired fasting glucose
and/or the presence of impaired glucose tolerance) and diabetes
remained significantly associated with GD (OR 1.27, 95% CI
1.06–1.61; OR 1.27, 95% CI 1.006–1.61, respectively).
In the overall series lipid parameters (total and HDL cholesterol,
triglycerides, analyzed both as continuous and as categorical
variables), bilirubin and other liver enzymes did not significantly
differ according to the presence of GD. No difference was also
observed between patients with GD diagnosed at the time of
NAFLD assessment and those with a diagnosis of GD based on
previous cholecystectomy.
At multivariate analysis (table 2), the variables independently
associated with GD were female gender, age, fasting glucose and
NASH, whereas ALT levels were associated with a lower risk.
When the 33 subjects with cirrhosis were excluded from the
analysis, GD was significantly associated with fasting glucose,
female gender and NASH. Excluding from the analysis the 144
patients with diabetes, NASH remained the only independent
variable associated with GD.
Discussion
In this large series of well-characterized Italian patients with
biopsy-proven NAFLD we provide evidence for an association of
GD with glucose alterations, NASH and severe fibrosis, without
difference in the severity of steatosis.
A few papers have already suggested the existence of an
association between GD and NAFLD [24,25]. This association
might stem from the pathogenic factors shared by both GD and
NAFLD, given that the risk for GD is especially high in patients
with central obesity, type 2 diabetes and insulin resistance
[12,13,14,26,27]. All these conditions are components of the
metabolic syndrome and NAFLD itself is considered the hepatic
expression of the metabolic syndrome. However, despite the
association of NASH and GD was tentatively related to central
obesity [28], BMI and large waist circumference were not
significantly associated with GD at multivariate analysis.
The strength of the study is the very large sample size of well-
characterized, biopsy proven NAFLD patients, which provided a
reasonable number of GD cases to characterize risk factors for GD
in relation to histology. The overall prevalence of GD in our series
was 20%, a value similar to that previously reported in another
Italian NAFLD series [24] and slightly higher than in the general
population (3.3–14.8%) [10,11]. As expected, GD remained
significantly associated with female gender. The prevalence of
GD was higher in subjects with the metabolic syndrome, in
keeping with the results reported in the general population and in
obese subjects [29]. The metabolic syndrome was significantly
associated with GD at univariate analysis, even when adjusted for
gender and age, but the significance was lost at multivariate
analysis, at variance from data reported by Mendez-Sanchez et al
[30] in a smaller series.
Of note, fasting glucose level, not the presence of diabetes,
remained significantly associated with GD at multivariate analysis.
In a population-based case-control analysis of the UK General
Practice Research Database (22,574 cases with cholecystectomy
and 72,476 controls), Bodmer et al concluded that neither the
presence or duration of diabetes, nor metabolic control or use of
oral antidiabetic therapies were associated with an altered risk of
cholecystectomy [31]. In contrast, the risk of biliary disease
(defined as occurrence of cholelithiasis, acute cholecystitis, or
cholecystectomy) was reported to be 1.9-fold increased in a large
retrospective analysis of several U.S. health care claims databases
of patients with type 2 diabetes [32]. Differences might also derive
from different rates of statin use in NAFLD (8% of cases in our
series, with no difference in relation to the presence/absence of
GD), considering that a protective effect of statins on GD has been
reported in patients with and without diabetes [31], an effect that
might also extend to protection against NASH [33].
From a pathogenic perspective, hepatic insulin resistance, the
metabolic milieu of steatosis, is associated with biliary cholesterol
secretion, a mechanism to explain cholesterol gallstone formation
[34]. Clinical studies confirmed that insulin resistance could have a
major role in the pathogenesis of GD, by favoring the production
of cholesterol-supersaturated bile and by altering gallbladder
function [17]. However in our series we found an association of
GD with HOMA only at univariate, not at multivariate analysis,
possibly because of the high proportion of patients with diabetes
and the wide range of glucose levels, entering the predictive model
and limiting the significance of HOMA-IR. No association with
serum bilirubin and alkaline phosphatase levels was detected,
Figure 1. Percentage of necro inflammatory grading (left),
fibrosis staging (middle) and steatosis (right) according to the
presence or absence of GD. For necroinflammatory grade (IV =
grade IV, V, VI and VII together). Analysis for trend: Necroinflammatory
grade p= 0.01, Fibrosis stage p= 0.0001, Steatosis not significant
(p = 0.7).
doi:10.1371/journal.pone.0041183.g001
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indirectly excluding the presence of bile duct stones as a
contributing factor to more severe liver disease in patients with
GD.
Unexpectedly, ALT levels were significantly lower in patients
with GD, either when ALT were analyzed as continuous variables
or when categorized as values above normal range, although GD
was significantly associated with more severe histological liver
damage. A poor prognostic significance of elevated ALT has been
reported in several series of NAFLD patients [18,35], but it
remains difficult to explain these finding on a mechanicistic base.
Table 1. Anthropometric, biochemical and clinical variables in patients with NAFLD with or without GD (univariate analysis).
Variables GD (n=107) non GD (n=417) P value+ OR for GD 95% CI
Female gender* 48 (45%) 103 (25%) 0.0001 1.57 1.26–1.96
Age* (yrs) 54612 47613 0.0001 1.05 1.03–1.07
BMI (kg/m2) 29.665.2 28.164.6 0.01 1.06 1.01–1.11
Overweight/obesity (BMI $25 kg/m2) 91 (85%) 316 (76%) 0.05 1.7 1.01–3.3
Large waist circumference (male .102, female .88 cm) 68 (64%) 15 (36%) 0.02 1.46 1.12–1.94
Fasting glucose* (mmol/L) 6.863.0 5.861.7 0.001 1.21 1.1–1.301
Prediabetes (fasting glucose $5.5 mmol/L and or impaired
glucose tolerance)*
59 (55%) 150 (36%) 0.0003 1.49 1.20–1.86
Diabetes* 44 (41%) 11 (26%) 0.002 1.82 1.13–78
HOMA-IR 6.266.1 4.664.3 0.03 1.05 1.003–1.11
Triglycerides (mg/dL) 146677 146681 0.1 0.99 0.99–1.00
Triglycerides $150 (mg/dL) 43 (40%) 154 (37%) 0.5 0.93 0.94–1.17
Total cholesterol (mg/dL) 196642 201644 0.2 0.99 0.99–1.00
HDL-cholesterol (mg/dl) 48614 45612 0.99 0.99 0.99–1.00
Males 47613 44612 0.1 1.00 0.99–1.0
Females 50616 48612 0.6 1.01 0.97–1.04
Serum ferritin (ng/ml) 2506208 2886277 0.1 0.99 0.99–1.01
ALT* (U/L) 51628 65640 0.0001 0.88 0.91–0.94
AST/ALT* 0.8460.4 0.7160.31 0.0001 2.0 1.0–4.0
Arterial hypertension 43 (40%) 158(38%) 0.8 0.98 0.77–1.02
Metabolic syndrome* 54 (50%) 133 (31%) 0.0007 1.48 1.17–1.85
NASH* 83 (77%) 233 (56%) 0.0001 1.64 1.29–2.11
Mean 6 SD or number of cases and (%).
+P-values (ANOVA or chi-square test).
*Variables that maintained significance when the subjects diagnosed with cirrhosis were excluded from analysis.
doi:10.1371/journal.pone.0041183.t001
Table 2. Adjusted risks associated with GD in the overall series, in patients without cirrhosis and without diabetes, at multivariate
logistic regression analysis.
Patients All Patients without cirrhosis Patients without diabetes
Variables OR adj 95% CI OR adj 95% CI OR adj 95% CI
Female gender 1.44 1.07–1.92 1.44 1.06–1.47 1.30 0.96–1.85
Age (yrs) 1.03 1.00–1.04 1.01 1.00–1.04 1.05 1.01–1.07
Overweight/obesity (BMI .25 kg/m2) 1.05 0.73–1.48 0.95 0.67–1.30 1.01 0.84–1.09
Waist circumference (M .102, F .88 cm) 1.00 0.96–1.34 1.00 0.97–1.03 0.98 0.93–1.03
Fasting glucose (mmol/L) 1.15 1.00–1.35 1.18 1.00–1.10 1.06 0.98–1.03
Diabetes 1.24 0.83–1.86 0.75 0.48–1.13 – –
HOMA-IR 1.18 0.82–1.74 1.03 0.96–1.10 1.02 0.83–1.87
ALT U/L 0.98 0.97–0.99 0.98 0.97–0.99 0.99 0.98–1.00
AST/ALT 1.15 0.80–2.70 1.69 0.73–3.84 0.33 0.6–1.07
Metabolic Syndrome 1.16 0.84–1.59 1.09 0.81–1.49 1.2 0.89–1.78
NASH 1.46 1.08–1.99 1.51 1.14–2.15 1.5 1.10–2.10
Each variable adjusted for the others in the table.
doi:10.1371/journal.pone.0041183.t002
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GD is not systematically associated with raised ALT [36,37].
Interestingly Ioannou et al [36], analyzing cohort data from the
first National Health and Nutrition Examination Survey
(NHANES), found that cholelithiasis was independently associated
with cirrhosis, not with serum liver enzymes. In our series, the
higher necroinflammatory activity observed in GD would be
expected to be associated with a risk of raised liver enzymes, but
the pattern of aminotransferases levels changes with progressive
disease and steatosis tend to disappear in more advanced NAFLD.
This observation requires additional studies.
Our study has clinical relevance. About half of the patients with
GD undergoing liver biopsy at the time of cholecystectomy were
reported to have NAFLD [25], suggesting the opportunity of a
routine liver biopsy during surgery to establish an early diagnosis
of NAFLD, a policy supported by a NHANES report [36] and by
a recent EASL Consensus for liver biopsy in NAFLD [38].
Limitations and Strengths
Major limitations of the study are the small group of cases with
previous cholecistectomy, which did not allow evaluate whether
these patients have different hepatic outcome. Similarly, the low
number of patients with cirrhosis did not permit a separate analysis
of risk factors in this cohort. The strength of the study is the large
number of patients with biopsy proven NAFLD who were
evaluated for GD.
In conclusion, although the cross-sectional nature of the study
does not allow to completely understand the cause-effect relation-
ship between GD and NASH, the presence of GD in a subject with
steatosis deserves consideration as a possible risk of liver disease
severity. A liver biopsy in these cases should always be considered,
because of the higher risk of NASH and severe fibrosis. Cases with
hyperglycemia/diabetes might be worth a more careful scrutiny.
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